Physician profile
Milan Banjanin
NPI 1316035355
$4,025.74
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,024 · 2020: $618 · 2021: $93.18 · 2022: $171 · 2023: $19.62 · 2024: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $100 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.21 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $649.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $475.65 | 2019-2022 | |
| Pfizer INC. | $465.62 | 2019-2020 | |
| Amgen INC. | $377.54 | 2019-2021 | |
| Lilly USA, LLC | $348.11 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $301.70 | 2019-2020 | |
| Novo Nordisk INC | $285.42 | 2019-2020 | |
| Edwards Lifesciences Corporation | $100.21 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $87.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $87.44 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $71.41 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $56.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.60 | 2019 | |
| Allergan, INC. | $31.44 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $23.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Astellas Pharma US INC | $18.53 | 2019 | |
| Philips North America LLC | $17.56 | 2019 | |
| Horizon Therapeutics Plc | $13.34 | 2020 | |
| Boston Scientific Corporation | $11.77 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.10 | 2019 | |
| Glaxosmithkline, LLC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Banjanin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.